HK1252752A1 - 新型吡唑並嘧啶衍生物 - Google Patents

新型吡唑並嘧啶衍生物

Info

Publication number
HK1252752A1
HK1252752A1 HK18112077.1A HK18112077A HK1252752A1 HK 1252752 A1 HK1252752 A1 HK 1252752A1 HK 18112077 A HK18112077 A HK 18112077A HK 1252752 A1 HK1252752 A1 HK 1252752A1
Authority
HK
Hong Kong
Prior art keywords
pyrimidine derivatives
novel pyrazolo
pyrazolo pyrimidine
novel
derivatives
Prior art date
Application number
HK18112077.1A
Other languages
English (en)
Inventor
Karen Kammertoens
Jean Quancard
Achim Schlapbach
Oliver Simic
Marina Tintelnot-Blomley
Grahame Woollam
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1252752A1 publication Critical patent/HK1252752A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112077.1A 2015-11-13 2018-09-19 新型吡唑並嘧啶衍生物 HK1252752A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194627 2015-11-13

Publications (1)

Publication Number Publication Date
HK1252752A1 true HK1252752A1 (zh) 2019-05-31

Family

ID=54542128

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112077.1A HK1252752A1 (zh) 2015-11-13 2018-09-19 新型吡唑並嘧啶衍生物

Country Status (15)

Country Link
US (1) US20200289514A1 (zh)
EP (1) EP3374361A1 (zh)
JP (1) JP2018533610A (zh)
KR (1) KR20180080311A (zh)
CN (1) CN108473499B (zh)
AU (1) AU2016352813B2 (zh)
BR (1) BR112018009511A2 (zh)
CA (1) CA3003820A1 (zh)
HK (1) HK1252752A1 (zh)
IL (1) IL259169A (zh)
MX (1) MX2018005390A (zh)
PH (1) PH12018500932A1 (zh)
SG (1) SG11201803480WA (zh)
WO (1) WO2017081641A1 (zh)
ZA (1) ZA201802743B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3384903T (pt) 2011-11-18 2020-06-25 Regeneron Pharma Micropartícula contendo proteína terapêutica revestida com polímero biodegradável para uso médico
RU2019104890A (ru) 2016-07-29 2020-08-31 Люпин Лимитед Замещенные тиазолопиридиновые соединения в качестве ингибиторов malt1
MA53299A (fr) 2016-07-29 2022-02-23 Lupin Ltd Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
JP7296407B2 (ja) * 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
WO2020111087A1 (ja) * 2018-11-28 2020-06-04 武田薬品工業株式会社 複素環化合物
CN109503473B (zh) * 2019-01-07 2020-07-07 上海慧川生物医药科技有限公司 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
BR112021019799A2 (pt) 2019-04-11 2021-12-07 Janssen Pharmaceutica Nv Derivados contendo anéis de piridina como inibidores de malt1
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
JPWO2021241611A1 (zh) 2020-05-27 2021-12-02
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
CN116710089A (zh) * 2020-11-12 2023-09-05 莫诺泰罗斯疗法公司 治疗癌症的材料和方法
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2023107721A1 (en) * 2021-12-10 2023-06-15 Rheos Medicines, Inc. Methods for treating diseases using malt1 inhibitors
WO2023139479A1 (en) * 2022-01-18 2023-07-27 Aurigene Oncology Limited Substituted bicyclic heterocycles as malt-1 inhibitors
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
EP1505068A4 (en) * 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2705694C (en) 2007-11-21 2015-02-24 Katholieke Universiteit Leuven, K.U.Leuven R & D Inhibitors of malt1 proteolytic activity and uses thereof
SI3149001T1 (sl) * 2014-05-28 2019-08-30 Novartis Ag Novi derivati pirazolo pirimidina in njihova uporaba kot inhimitorji malt1
EP3535254A4 (en) * 2016-11-01 2020-06-24 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") COMPOUNDS FOR THE DEGRADATION OF MALT1

Also Published As

Publication number Publication date
ZA201802743B (en) 2019-01-30
MX2018005390A (es) 2018-08-16
CN108473499A (zh) 2018-08-31
AU2016352813B2 (en) 2019-09-19
JP2018533610A (ja) 2018-11-15
BR112018009511A2 (pt) 2018-11-06
IL259169A (en) 2018-07-31
CN108473499B (zh) 2021-07-23
EP3374361A1 (en) 2018-09-19
KR20180080311A (ko) 2018-07-11
PH12018500932A1 (en) 2019-01-28
AU2016352813A1 (en) 2018-05-10
SG11201803480WA (en) 2018-05-30
CA3003820A1 (en) 2017-05-18
WO2017081641A1 (en) 2017-05-18
US20200289514A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
HK1252752A1 (zh) 新型吡唑並嘧啶衍生物
HK1255921A1 (zh) 嘧啶化合物
IL261885A (en) Pyrazolopyrimidine history
HK1255045A1 (zh) 取代的氧代吡啶衍生物
HK1245249A1 (zh) 二環喹唑啉酮衍生物
EP3129377A4 (en) Mertk-specific pyrimidine compounds
EP3262048A4 (en) Antiviral compounds
IL253381A0 (en) History of h9-pyrrolo-dipyridine
IL248005B (en) Macrocyclic pyrimidine histories
GB201514489D0 (en) Hyperphenylalaninemia
EP3202762A4 (en) Pyrimidinone compound
IL250022A0 (en) New converted pyrimidine compounds
HK1247192A1 (zh) 吡啶或嘧啶衍生物
PL3359543T3 (pl) Pochodne kukurbiturylu
AP2016009506A0 (en) Pyrimidine compound
SG11201803357TA (en) Pyrimidine derivative
IL251005B (en) Pyrido-oxazinone derivatives
EP3372588A4 (en) pyrimidine
EP3312172A4 (en) aminopyrazole
IL248900A0 (en) pyrazine derivatives
HK1245796A1 (zh) 黃嘌呤衍生物